SCHEMBL6080098

SCHEMBL6080098

COCC(O)CNS(=O)(=O)c1ccc2cc(Cl)ccc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.58
GAA P10253 3/20 0.58
KMT2A Q03164 3/20 0.58
PKM P14618 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
SLC6A9 P48067 1/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
POLB P06746 1/20 0.43
F2 P00734 1/20 0.42
MEN1 O00255 2/20 0.41
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.40
ADRB2 P07550 2/20 0.40
CA12 O43570 1/20 0.40
ADRB1 P08588 1/20 0.40
CA9 Q16790 1/20 0.40
GSR P00390 2/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5729827 0.82 KMT2A (0.52) ALDH1A1GAAKMT2APKML3MBTL1
SCHEMBL7386698 0.79 ALDH1A1 (0.58) ALDH1A1GAAKMT2APKML3MBTL1
SCHEMBL7387529 0.77 ALDH1A1 (0.55) ALDH1A1GAAKMT2APKML3MBTL1
SCHEMBL6791925 0.76 ALDH1A1 (0.57) ALDH1A1GAAPOLBMAPTHTT
Hydrochloric Acid SCHEMBL7050781 0.76 GBA1 (0.56) ALDH1A1GAAKMT2APKML3MBTL1
SCHEMBL26395006 0.75 MAPT (0.52) ALDH1A1GAAKMT2APKML3MBTL1
SCHEMBL3905853 0.72 APEX1 (0.57) ALDH1A1GAAKMT2A
SCHEMBL6079464 0.71 ALDH1A1 (0.53) ALDH1A1GAAKMT2APKMMEN1
SCHEMBL7598374 0.70 NPC1 (0.47) ALDH1A1POLBF2
SCHEMBL5729430 0.70 ACACB (0.47) ALDH1A1GAAPOLBMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7122662-B2 Tricyclic compound having spiro union MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2006-10-17 US disclosed
US-20050148769-A1 Tricyclic compound having spiro union MOCHIDA PHARMACEUTICAL CO., LTD. 2005-07-07 US disclosed
US-20040063716-A1 Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 US disclosed
EP-1346994-A1 CHOLESTEROL BIOSYNTHESIS INHIBITORS CONTAINING AS THE ACTIVE INGREDIENT TRICYCLIC SPIRO COMPOUNDS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063716-A1 Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds VKORC1, CYP46A1, TFPI ALDH1A1 1517/4885GAA 2819/4885KMT2A 2943/4885
US-20050148769-A1 Tricyclic compound having spiro union TFPI, F2, F12 ALDH1A1 1791/4885GAA 4117/4885KMT2A 3342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.